. Colistin reference MICs were determined using frozen panels according to ISO standard 20776-1. An international collection of Gram-negative bacteria (n¼75) with varying levels of colistin susceptibility was tested. Results: The colistin BMD products correlated well with reference tests, in particular for Sensititre and the two MICRONAUT products (essential agreement 96%: 66/69 (96%, CI 88e99%), 72/75 (96%, CI 88e 99%) and 74/75 (99%, CI 92e100%)). The results were somewhat poorer for the BMD products SensiTest and UMIC: EA 88% (51/58, CI 77e95%) and 82% (61/74, CI 72e89%), respectively), and considerably poorer for the gradient tests (EA 43e71% depending on gradient test and Mueller-Hinton agar manufacturer). The gradient tests generally underestimated colistin MICs, resulting in a significant number of false susceptible results (9e18 of total 75 tests, compared with 1e3 for the BMD products). Conclusions: Based on the results of this study, we advise laboratories not to trust gradient tests for colistin susceptibility testing and to use broth microdilution methods for this purpose. There are several commercial broth microdilution tests available and in principle they perform well. E. Matuschek, Clin Microbiol Infect 2017;▪:1 © 2017 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Introduction
An accurate method for antimicrobial susceptibility testing (AST) of colistin (polymyxin E) is crucial in an era of increasing numbers of multi-resistant Gram-negative bacteria and simultaneous increasing colistin resistance. The reference methodology for AST is MIC determination with broth microdilution (BMD) according to the ISO standard 20776-1 [1] . However, BMD of colistin is associated with methodological issues. Colistin binds to the plastic of polystyrene trays and attempts have been made to prevent this by adding a surfactant, such as polysorbate-80, to the test system [2, 3] . Recently, a joint CLSI-EUCAST working group investigated colistin BMD testing and decided that the recommendations in the ISO standard should be adhered to and that testing should be performed using the sulphate salt of colistin and standard polystyrene trays without the addition of surfactants [4] . The working group showed that surfactants did not improve assay performance and that there is, in fact, a synergistic effect with colistin (J. Turnidge, personal communication).
Clinical microbiology laboratories only rarely perform reference broth microdilution, which requires freshly prepared or frozen antibiotic solutions. However, a number of more user-friendly commercial products for colistin BMD have recently become available. Methods widely used for AST at clinical laboratories are gradient tests, disk diffusion, and semi-automated devices. For many years, both CLSI and EUCAST have advised against the use of disk diffusion testing for colistin AST. Gradient tests and semiautomated AST devices have been extensively used at clinical laboratories, despite the problems reported with colistin AST on these systems [5, 6] .
The objective of this study was to evaluate five commercially available BMD products and the two available gradient tests for colistin MIC determination using frozen BMD panel MICs as reference. It was beyond the scope of the present investigation to evaluate semi-automated AST devices.
Materials and methods
Antimicrobial susceptibility testing was performed on an international collection of Gram-negative bacteria (n¼75): Escherichia coli (n¼14), Klebsiella pneumoniae (n¼18), Pseudomonas aeruginosa (n¼21), and Acinetobacter spp. (n¼22, of which 16 were Acinetobacter baumanii) with varying levels of colistin susceptibility, kindly provided by Paul Rhomberg, JMI Laboratories, USA (isolates from the worldwide SENTRY surveillance program); S€ oren Gatermann, Bochum, Germany; Rene Henriksen, Copenhagen, Denmark; Ørjan Samuelsen, Tromsø, Norway; Jordi Vila, Barcelona, Spain; and Luis Martinez-Martinez, Santander, Spain.
The isolates were identified to species level using the Microflex system with the MALDI Biotyper 3.1 software (Bruker Daltonics) and the MBT database-5627 according to the manufacturer's instructions. Colistin reference MICs were determined in accordance with the ISO standard 20776-1 [1] and CLSI/EUCAST recommendations [4] on frozen BMD panels (Thermo Fisher Scientific, Cleveland, OH, USA) with two-fold dilutions from 128 to 0.125 mg/ L. MIC determination for colistin was performed according to the manufacturers' instructions for seven commercially available MIC products. Five were BMD products with freeze-dried antibiotics: SEMPA1 (custom Sensititre plate, Thermo Fisher Scientific, East Grinstead, UK), MICRONAUT-S and MICRONAUT MIC-Strip (MERLIN Diagnostika Gmbh, Bornheim, Germany), SensiTest (Liofilchem, Roseto degli Abruzzi, Italy) and UMIC (Biocentric, Bandol, France). The Sensititre plate is designed to test one isolate against several antimicrobial agents including colistin, whereas the other products are for testing colistin only. The MICRONAUT-S is a 96-well panel for eight isolates, the SensiTest consists of a smaller panel for four isolates and the MICRONAUT MIC-Strip and UMIC are single-isolate tests consisting of a plastic device with 12 wells. If skipped wells were observed when reading the BMD panels, the isolates were retested. The two gradient test brands available at the time of the study, Etest (bioM erieux, Marcy l'Etoile, France) and MIC Test Strip (MTS, Liofilchem), were also investigated. Etest and MTS were tested on in-house prepared Mueller-Hinton (MH) agar plates using agar powder from Oxoid (Thermo Fisher Scientific, Basingstoke, UK) and BBL (BD, Sparks MD, USA) in parallel. Etest was also tested on the bioM erieux's Mueller Hinton E (MHE) medium as recommended by the manufacturer. The fully colistin-susceptible E. coli ATCC 25922 and P. aeruginosa ATCC 27853 and the mcr1-positive E. coli NCTC 13846 (CCUG 70662, DSM 105182) with a colistin MIC of 4 mg/L were used as quality control (QC) for all methods (6 tests per strain and method) and analysed vs. EUCAST QC Tables version 7.0 [7] . Essential agreement (EA ¼ MICs within ± 1 dilution of reference MICs) and categorical agreement (CA) were calculated according to ISO standard 20776-2 [8] vs. EUCAST Breakpoint Tables version 7.1 [9] using colistin MICs on frozen BMD panels as reference (susceptible 2, resistant >2 mg/L). There are no CLSI breakpoints for Enterobacteriaceae, but CLSI breakpoints for P. aeruginosa and Acinetobacter spp. are the same as for EUCAST [10] . For the BMD products Sensititre, SensiTest, and UMIC, the number of tests used to calculate the EA was lower than the total number of isolates because of truncations in the MIC panel ranges. The numbers of isolates included per the total numbers of isolates for Enterobacteriaceae (E. coli and K. pneumoniae), P. aeruginosa and Acinetobacter spp., respectively, were: Sensititre (28/32, 19/21, 22/ 22) SensiTest (26/32, 15/21, 17/22), and UMIC (32/32, 20/21, 22/22). The MIC values of the isolates not included in the EA calculations were either 0.25 or 32 mg/L (Fig. 1) .
The occurrence of mcr genes was investigated by whole-genome sequencing (WGS) all isolates with colistin reference MICs 2e8 mg/ L (n¼24) and the three Enterobacteriaceae with reference MICs 1 mg/L.
Results
Colistin reference MICs for the 75 Gram-negative bacteria were from 0.25 to 128 mg/L (Table 1) . A total of 24 isolates had MICs of 2, 4, and 8 mg/L, that is just below, on, and above the EUCAST breakpoints (susceptible 2, resistant >2 mg/L). The correlation with reference MICs was good for all BMD products with an expected 45-degree correlation (1:1 correspondence in the linear regression) across the full scale of MIC values (Fig. 1 ). However, skipped wells which required retesting occurred occasionally on all BMD panels. The correlation with reference MICs was poor for gradient tests and a 45-degree correlation could not be obtained with either of the gradient test-medium combinations tested (Fig. 1) . The correlation for the gradient tests was especially poor for isolates with MICs above the breakpoint (>2 mg/L).
None of the P. aeruginosa or Acinetobacter spp. analysed with WGS (colistin MICs 2e8 mg/L) contained any mcr genes. All E. coli with colistin 4 mg/L were positive for mcr-1, as well as one K. pneumoniae with 8 mg/L. One colistin-resistant E. coli (8 mg/L) contained both mcr-1 and mcr-3. One colistin-susceptible E. coli (1 mg/L) was positive for mcr-1 but tested susceptible with all methods.
Essential agreement
The highest essential agreement (EA: 96e99%) was obtained for Sensititre and the two MICRONAUT products (essential agreement 96%: 66/69 (96%, CI 88e99%), 72/75 (96%, CI 88e99%), and 74/75 (99%, CI 92e100%)), see Table 2 . For the broth microdilution singleisolate test from MICRONAUT (MIC-Strip), only one MIC was outside essential agreement. The results were poorer for SensiTest and UMIC, with EA of 88% (51/58, CI 77e95%) and 82% (61/74, CI 72e89%), respectively. The lowest EA was obtained for the gradient tests, which varied between 43% (32/75, CI 32e54%) and 71% (53/ 75, CI 60e80%), depending on the MH medium used ( Table 2 ). The correlation with reference MICs for gradient tests was best for Etest on Oxoid MH and poorest for Etest on BBL MH agar.
For Sensititre and the two MICRONAUT products, the tests performed well for all species investigated (EA 91e100% depending on species). For the two other BMD products, the test performance varied depending on the species investigated, with poorer performance (EA <80%) for Acinetobacter spp. on SensiTest and for both P. aeruginosa and Acinetobacter spp. on UMIC. For the gradient tests, there were marked differences between the species investigated, with the poorest EA for Acinetobacter spp., which was below 10% (1/ 22 (5%, CI 1e22%) and 2/22 (9%, CI 3e28%) for Etest on BBL MH and MHE. However, also for E. coli, K. pneumonia, and P. aeruginosa, EA was generally low.
Categorical agreement
The categorical agreement (number of tests with correct susceptibility categorization) varied from 89% to 95% for the BMD products and from 76% to 85% for the gradient tests. The BMD products tended to overestimate MICs to a small extent, both for susceptible and resistant isolates (Fig. 1) , resulting in some major errors, that is false resistant results ( Table 2 ). Most of these (12/25) were for Acinetobacter spp. There were also a few very major errors (false susceptible results) for the two MICRONAUT tests, SensiTest and UMIC, and the majority of these (6/8) were for P. aeruginosa. Gradient tests generally underestimated MICs, especially in the area above the breakpoint, resulting in a significant number of very major errors, that is false susceptible results (9e18 per testmedium combination of a total of 75 tests), whereas false resistant results were few (0e2).
Most QC results were within acceptable ranges ( absolutely essential for laboratories to report correct results and good essential agreement is more important than for many other antimicrobial agents. Gradient tests performed slightly better for isolates that lacked colistin resistance mechanisms (MICs 2 mg/L) than for colistinresistant isolates (MICs >2 mg/L). For some time, it was hoped that a susceptible result could be trusted even if the ability to predict the level of resistance was poor. However, our results indicate that although isolates without colistin resistance were mostly categorized as susceptible, isolates with colistin resistance mechanisms could be categorized as susceptible or resistant. Furthermore, the essential agreement was poor also for susceptible isolates, resulting in underestimation of colistin MICs for both susceptible and resistant isolates. It is likely that the poor correlation between gradient tests and BMD reference MICs is related to the poor diffusion of colistin in agar. A similar poor correlation was observed for disk diffusion, which was performed in parallel using colistin disks with three potencies (10, 25 , and 50 mg) on a subset of the isolates in this study (data not shown). None of the disks could discriminate between colistin susceptible and resistant isolates. The gradient tests performed better for E. coli and K. pneumoniae than for P. aeruginosa and Acinetobacter spp., but in our opinion, the major problems with colistin gradient tests shown in this study deem those products unreliable for colistin MIC determination in any species.
Commercial BMD products correlated significantly better with reference methodology than the gradient tests. False susceptible results (very major errors) were mainly obtained for P. aeruginosa, which is not surprising as the susceptible breakpoint was set at 2 mg/L, whereas the epidemiological cut-off (ECOFF) is 4 mg/L. Please cite this article in press as: Matuschek E, et al., Antimicrobial susceptibility testing of colistin e evaluation of seven commercial MIC products against standard broth microdilution for Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter spp., Clinical Microbiology and Infection (2017), https://doi.org/10.1016/j.cmi.2017.11.020
It is therefore likely that even a well-calibrated method will, to some extent, underestimate colistin resistance in P. aeruginosa.
As discussed by several other authors, colistin MIC determination is associated with methodological difficulties [2, 3, 11, 12] . This study was not designed to further investigate the effect of adding surfactants or other modifications to the reference methodology, but to evaluate commercial products for colistin MIC determination. Our results show that colistin MIC determination can be performed with reproducible results using both reference BMD methodology and commercial BMD products.
When analysing the quality control (QC) data, it was obvious that the regular susceptible QC strains could not disclose the poor ability of gradient tests to predict colistin resistance. Furthermore, the QC ranges, consisting of four two-fold dilutions, recommended by both EUCAST and CLSI for E. coli ATCC 25922 and P. aeruginosa ATCC 28753 allow significant variation in colistin MICs regardless of method used. Such variation is not acceptable when testing clinical isolates. We strongly recommend that the colistin-resistant E. coli NCTC 13846 (CCUG 70662, DSM 105182) is included in all colistin susceptibility testing. For this strain, the expected colistin MIC is 4 mg/L, and in our experience it is reasonable to expect almost all results between 2 and 8 mg/L and >80% on 4 mg/L. BMD is commonly regarded as a laborious and expensive method, but the commercial BMD products evaluated in this study are easy to use and do not require additional equipment or great expertise. It should therefore be possible for clinical microbiology laboratories to internally validate any of these products for reliable colistin MIC testing and to completely stop using gradient tests for this purpose.
All testing in this study was performed by skilled staff in a laboratory performing broth microdilution daily and quality control was performed throughout the study. Ideally, we would have performed all tests on the same day, from the same inoculum suspension, with the same Mueller-Hinton broth, etc., but this was not logistically possible, which is a limitation of this study. We believe the comparisons were as fair as is possible. We would, however, like to stress that when evaluating antimicrobial susceptibility tests, it is possible to achieve results which are better or worse by choosing easier or more difficult isolates for the evaluation. If isolates are chosen which are clearly at different ends of the spectrum of susceptibility, numbers of errors are going to be low. If isolates close to the breakpoints are chosen, numbers of errors are going to be higher. On the other hand, if breakpoints allow for a wide intermediate category, there will be very few major or very major errors. In this study, isolates were difficult and many of them had colistin MIC values close to the breakpoints. As neither EUCAST nor CLSI have introduced an intermediate category, errors will be either major errors or very major errors. These factors make our comparison a challenging one to the tests we evaluated.
Conclusions
Commercial broth microdilution methods generally performed well with the best correlation for Sensititre and the two MICRO-NAUT tests, whereas the performance of the two gradient tests was unacceptable. This is probably related to the poor, and possibly unpredictable, diffusion of colistin in agar.
Based on the results of this study, we advise laboratories not to trust colistin gradient tests or disk diffusion and to use broth microdilution methods for this purpose. This advice has been adopted by EUCAST. There are several commercial and userfriendly broth microdilution tests available on the market. However, a favourable result for a commercial product in this study does not mean that EUCAST recommends or endorses this particular product. The need for stringent quality control of any method is emphasized and we recommend that all laboratories performing colistin MIC determination include the colistin resistant E. coli NCTC 13846 for quality control. The colistin MIC target value for this strain is 4 mg/L and should only occasionally be 2 or 8 mg/L. We did not have the opportunity to validate the performance of semiautomated AST devices in this study, but others have reported poor performance for colistin with these [5, 6] .
